| Old Articles: <Older 36561-36570 Newer> |
|---|
 |
The Motley Fool
May 29, 2009
Chris Hill |
2 Stocks on Our Radar GM, United Airlines, Microsoft, and Logitech are companies discussed in this week's podcast.   |
The Motley Fool
May 29, 2009
Toby Shute |
This Tanker's Built Tough Tanker titan Frontline manages to generate about $77 million in earnings, beating the median analyst estimate by over 50%. |
The Motley Fool
May 29, 2009
Rich Smith |
Coca-Cola's Weak Brew, Take Two Last year Coke teamed up with Italy's illycaffe to create a joint venture to hawk canned, ready-to-drink coffee concoctions -- "Caffe," "Cappuccino," and "Latte Macchiato" under the "illy issimo" brand name. How has it gone? |
The Motley Fool
May 29, 2009
Christopher Barker |
What the Crashing Dollar Means for You Each successive moment of truth for the greenback carries greater significance. |
The Motley Fool
May 29, 2009
Brian Orelli |
The "Naughty List" You Want Your Company On Athenahealth is out with its annual review of how quickly health insurers are paying the claims that doctors make for services. |
The Motley Fool
May 29, 2009
Toby Shute |
It's Time to Take Note of Talisman Around this time last year, Talisman Energy unveiled a serious strategic overhaul. Now that we're a year into the transformation, it's a perfect time to take a look at how the firm's performing. |
The Motley Fool
May 29, 2009
Brian Orelli |
The Clouds Are Parting The Food and Drug Administration has scheduled an advisory committee meeting for Aug. 4 to get input on whether the agency should approve generic versions of ViroPharma's antibiotic, Vancocin. |
The Motley Fool
May 29, 2009
Dan Caplinger |
These Stocks Are Cheap by Every Measure Unfortunately, when a bear market pushes the price down on nearly every stock, the common ways of combing through stocks' valuations to find attractive candidates often turn up companies that aren't really great values right now. |
The Motley Fool
May 29, 2009
Brian Orelli |
Merck's Bad News Nothing to Sneeze At The U.S. Patent and Trademark Office reexamination of Merck's patent on allergy medication, Singulair, is nothing to sneeze at. The $2.8 billion worth of Singulair that Merck sold in the U.S. last year made up 12% of its total pharmaceutical sales. |
The Motley Fool
May 29, 2009
Tim Beyers |
Stocks to Avoid Now? Sometimes insiders are selling for all the right reasons. Who's selling this week: IBM... IPG Photonics... Princeton Review... |
| <Older 36561-36570 Newer> Return to current articles. |
